In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

在充满挑战的市场环境中，Myriad Genetics, Inc. (MYGN)股价触及52周新低，跌至16.6美元。这一最新价格走势反映出过去一年1.15%的温和增长，表明在更广泛的市场波动中经历了一段相对稳定的时期。投资者正密切关注公司的表现，因为股价在52周范围的低端附近波动可能表明对那些希望利用医疗保健板块动态的投资者来说既存在潜在风险也有机会。 在其他近期新闻中，Myriad Genet ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target ...

1 On November 1, 2024, UnitedHealthcare ("UNH") updated its medical policy for commercial and individual exchange plans to ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Thank you, Briana. Good afternoon, and welcome to Tempus’ third quarter 2024 conference call. This afternoon, Tempus released results for the quarter ending September 30, 2024. Joining me today from ...